Jacobs Levy Equity Management’s Inovio Pharmaceuticals INO Stock Holding History

Jacobs Levy Equity Management’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-130,792	Closed	-$228K	–	1013
2025 Q4	$228K	Buy	130,792 +113,119	+640%	+$249K	﹤0.01%	879
2025 Q3	$41.4K	Buy	+17,673	New	+$33.8K	﹤0.01%	952
2024 Q3	–	Sell	-16,497	Closed	-$133K	–	999
2024 Q2	$133K	Hold	16,497	–	–	﹤0.01%	929
2024 Q1	$229K	Sell	16,497 -79,334	-83%	-$685K	﹤0.01%	882
2023 Q4	$586K	Hold	95,831	–	–	﹤0.01%	805
2023 Q3	$447K	Sell	95,831 -83,112	-46%	-$459K	﹤0.01%	825
2023 Q2	$959K	Buy	178,943 +80,768	+82%	+$651K	0.01%	701
2023 Q1	$966K	Buy	+98,175	New	+$1.67M	0.01%	702
2020 Q1	–	Sell	-77,298	Closed	-$3.06M	–	1042
2019 Q4	$3.06M	Buy	+77,298	New	+$2.33M	0.03%	465
2019 Q2	–	Sell	-32,950	Closed	-$1.48M	–	981
2019 Q1	$1.48M	Buy	32,950 +12,108	+58%	+$610K	0.02%	577
2018 Q4	$1M	Buy	20,842 +1,875	+10%	+$114K	0.02%	598
2018 Q3	$1.26M	Buy	18,967 +14,709	+345%	+$819K	0.02%	609
2018 Q2	$200K	Sell	4,258 -2,509	-37%	-$138K	﹤0.01%	955
2018 Q1	$382K	Sell	6,767 -408	-6%	-$22.1K	0.01%	820
2017 Q4	$356K	Buy	+7,175	New	+$445K	0.01%	819

Other funds holding INO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jacobs Levy Equity Management's INO Position: Q1 2026 in Review

Jacobs Levy Equity Management sold out of Inovio Pharmaceuticals (INO) in Q1 2026, closing a stake of 130,792 shares — an estimated $228K sold.

Jacobs Levy Equity Management first reported a position in INO in Q4 2017 and held it in 15 quarters. The position peaked at $3.06M in Q4 2019. 100 funds tracked by Wall St. Rank hold INO as of Q1 2026.

Jacobs Levy Equity Management reported no remaining Inovio Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Jacobs Levy Equity Management sold 130,792 Inovio Pharmaceuticals shares in Q1 2026, an estimated $228K.
Jacobs Levy Equity Management first reported a position in Inovio Pharmaceuticals in Q4 2017 and held it in 15 quarters.
Jacobs Levy Equity Management's Inovio Pharmaceuticals position peaked at $3.06M in Q4 2019.
100 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.